Fresh off its filing for a new COPD drug, Massachusetts-based Sunovion Pharmaceuticals struck a $642 million deal to acquire Toronto-based Cynapsus Therapeutics and its Parkinson’s disease drug candidate.
Featured Posts
Pipelines Report 2023: innovation and diversification - Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.Medivir AB announced that it plans to split up into two independent companies.
Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.
Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.
The EPICUP test is a new tool that helps identify up to 87% of cases of cancer of unknown origin (CUP).
Regeneron and Sanofi announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent (alirocumab) Injection.
Adults with longer-lived parents have a lower-than-average risk for problems with the body’s circulatory system in middle age, British researchers have found.
Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.
Novartis AG said a late-stage study showed its oral once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
Eating a handful of nuts five times per week may reduce inflammation, a condition that contributes to heart disease, diabetes and many other chronic illnesses, say the authors of a recent U.S. study.